1
Dolutegravir Impact on Residual Replication
Condition(s):HIVLast Updated:November 20, 2017Completed
Tivicay PD: 6 Clinical Trials
Hide Studies Not Open or Pending
2
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
Condition(s):HIV-1-infectionLast Updated:July 28, 2021Recruiting
3
Dolutegravir + Rilpivirine Switch Study (DORISS)
Condition(s):HIV Infection; HAART-treated; Virologically ControlledLast Updated:August 28, 2015Withdrawn
4
BTZ-043 – Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
Condition(s):Pulmonary Tuberculoses; Other Specified Pulmonary TuberculosisLast Updated:February 24, 2022Active, not recruiting
5
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Condition(s):Infection, Human Immunodeficiency VirusLast Updated:January 16, 2018Completed
6
Triple vs. Double Therapy in naïves HIV-Infected Patients
Condition(s):HIV InfectionLast Updated:August 18, 2020Recruiting